RxDoctor Payments Data

Andrew Monfee, MD

Family Medicine · Russellville, ARNPI 1447257142

Payments from drug & device makers

$794in general payments, 2019–2025

Across 50 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$241
  • AbbVie$174
  • AstraZeneca$122
  • Amarin Pharma, Inc.$60
  • Abbott$26
  • Sunovion Pharmaceuticals Inc.$23
  • plus $147 from 10 others

What the payments were for

  • Food & beverage$794100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$794 in reported general payments places this provider in the 55th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$424,575
Medicare patients
660
Services billed
7,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide217$220,470
FarxigaDapagliflozin Propanediol148$108,618
EliquisApixaban127$102,978
MounjaroTirzepatide85$90,108
JardianceEmpagliflozin67$45,934
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog77$37,852
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$32,722
XareltoRivaroxaban32$22,881
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$19,303
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$16,821
MyrbetriqMirabegron21$16,027
PremarinEstrogens, Conjugated32$11,335
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen508$10,212
MultaqDronedarone Hcl11$10,010
SymbicortBudesonide/Formoterol Fumarate37$8,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$241$220,470217 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$122$143,297216 claims
PfizerEliquis, Premarin$16$114,312159 claims
GSKTrelegy Ellipta, Breo Ellipta$12$38,46657 claims
Astellas Pharma US IncMyrbetriq$13$16,02721 claims
AbbVieSynthroid, Lexapro$174$10,765105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Russellville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →